Semaglutide: research overview

The short version

Semaglutide is a synthetic version of a hormone your gut naturally releases after eating. That hormone — GLP-1 — tells the pancreas to produce insulin and tells the brain you are full. Semaglutide does the same thing, but it is engineered to stay in the body for roughly a week instead of two minutes. The result: sustained appetite suppression, slower gastric emptying, and better glucose control.

The human evidence here is substantial. Large randomized controlled trials found mean body-weight losses around 15% in people with obesity ^[4], reduced cardiovascular events in people with established heart disease ^[3], and reduced kidney-disease events in people with type 2 diabetes and chronic kidney disease ^[2]. Semaglutide is an FDA-approved prescription medicine for type 2 diabetes, chronic weight management, and cardiovascular risk reduction. It is not a supplement and not available over the counter. This page reports what the studies found; it does not recommend any dose or use.

What it is

Semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing approximately 94% sequence homology with the native hormone. Two structural modifications extend its half-life: an alanine-to-Aib substitution at position 8 blocks cleavage by DPP-4 (the enzyme that degrades native GLP-1 in about two minutes), and a C18 fatty di-acid side chain attached via a glutamic-acid/ADO spacer drives tight, reversible binding to serum albumin, which protects it from renal clearance. The combined result is a half-life of roughly one week — the basis for once-weekly dosing.

It is approved as a subcutaneous injection and, separately, as an oral tablet. The oral formulation is co-formulated with SNAC, an absorption enhancer, and its bioavailability is approximately 0.4–1%.

How it works

By activating the GLP-1 receptor, semaglutide does several things at once:

Pancreatic effects. It potentiates glucose-dependent insulin secretion from beta cells and suppresses inappropriate glucagon release from alpha cells — effects that are dependent on ambient glucose, which limits hypoglycemia risk in isolation.

Gastric effects. It slows gastric emptying, contributing to satiety and partly accounting for the nausea that is the dominant early side effect.

Central appetite effects. This is the primary driver of its weight effect. In rodent studies, semaglutide accessed the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus — appetite circuits — activating anorexigenic neurons and inhibiting hunger-promoting ones, reducing food intake and modifying food preference ^[6]. People often describe this as the "food noise" quieting.

Cardiovascular and renal effects. GLP-1 receptors are expressed on cardiac and renal tissue; their agonism contributes to pleiotropic protective effects documented in large outcomes trials ^[2][3][7].

What the research shows

Weight management (STEP 1). In the STEP 1 randomized controlled trial (n=1,961 adults with overweight or obesity, no diabetes), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body-weight change of -14.9% at 68 weeks versus -2.4% with placebo ^[4]. This is the cornerstone efficacy finding.

Head-to-head versus tirzepatide (SURMOUNT-5). When semaglutide was compared directly against tirzepatide in 751 adults with obesity, semaglutide produced -13.7% weight loss versus -20.2% with tirzepatide at 72 weeks (P<0.001) ^[1]. Tirzepatide was superior; semaglutide was not ineffective.

Cardiovascular outcomes (SELECT). In the SELECT trial (n=17,604 adults with preexisting cardiovascular disease and overweight or obesity but no diabetes), semaglutide 2.4 mg reduced major adverse cardiovascular events versus placebo — HR 0.80 (95% CI 0.72–0.90; P<0.001) — a 20% relative risk reduction ^[3].

Kidney outcomes (FLOW). In the FLOW trial (n=3,533 adults with type 2 diabetes and chronic kidney disease), semaglutide 1.0 mg reduced the composite of kidney failure, ≥50% eGFR decline, or kidney/cardiovascular death — HR 0.76 (95% CI 0.66–0.88) ^[2].

Early cardiovascular data (SUSTAIN-6). In 3,297 adults with type 2 diabetes at high cardiovascular risk, once-weekly semaglutide 0.5 or 1.0 mg reduced the primary MACE composite (HR 0.74; 95% CI 0.58–0.95) but raised diabetic-retinopathy complication rates among patients with pre-existing retinopathy undergoing rapid glycemic correction (HR 1.76; 95% CI 1.11–2.78) ^[7].

Safety profile (review). A dedicated safety assessment concluded that semaglutide has an overall favorable risk/benefit profile, with mild-to-moderate transient gastrointestinal effects as the dominant adverse event (nausea in roughly one-third of patients), increased biliary disease risk, and unconfirmed pancreatic and thyroid-cancer signals owing to low incidence ^[5].

Central mechanism (rodent). Mechanistic work showed semaglutide reduces body weight in rodents through distributed CNS pathways, directly accessing brainstem and hypothalamic circuits and reducing food intake without lowering energy expenditure ^[6].

Reported effects, cautions & safety

Community-reported effects (anecdotal, not clinical evidence).

People taking semaglutide consistently describe appetite suppression as the defining experience — what they call "food noise" going quiet. The constant background preoccupation with food fades, portion sizes drop to a third or half of prior intake, and cravings for sweets and fried foods diminish or disappear, sometimes within the first two weeks. Weight loss follows — steady and substantial over months, tied directly to eating much less. Some report blood-sugar readings improving markedly. An occasionally reported secondary effect is reduced interest in alcohol alongside the food-craving reduction.

On the side-effect side, nausea is by far the most common complaint, mentioned by roughly a third of people and often worst around dose increases; it typically eases within one to two weeks of a new dose. Foul-smelling "sulfur burps" come up repeatedly. Bowel changes — constipation and diarrhea, sometimes alternating — are common. Fatigue in the day or two after injection is frequently mentioned, especially early. A smaller group reports headaches, injection-site reactions, acid reflux, food aversions, and hair shedding (usually attributed to rapid weight loss rather than the drug itself). All of the above is anecdotal, self-reported, and unverified.

Safety cautions from the literature.

• Gastrointestinal intolerance: Nausea, vomiting, diarrhea, and constipation dominate the adverse-effect profile in trials and are the main reason people discontinue ^[5].
• Boxed warning — thyroid C-cell tumors: Rodent studies found C-cell tumors at supratherapeutic exposures; no clear human signal established, but the drug is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN-2 ^[5].
• Acute pancreatitis (class warning): Treatment is stopped if pancreatitis is suspected; no confirmed increase in pancreatic cancer in trials ^[5].
• Gallbladder disease: Increased cholelithiasis risk documented, attributed largely to the rate and magnitude of weight loss ^[5].
• Diabetic retinopathy: In SUSTAIN-6, retinopathy complications were higher in patients with pre-existing retinopathy undergoing rapid glycemic correction (HR 1.76) ^[7][5].
• Lean-mass loss: Body-composition substudies show a meaningful fraction of weight lost is lean mass, raising sarcopenia concerns ^[5].
• Weight regain after stopping: STEP 1 extension and STEP 4 data show substantial regain after discontinuation — framing this as a chronic, not curative, intervention ^[5].
• Pregnancy: Contraindicated; the approximately one-week half-life means discontinuing well before a planned conception is advised.
• Drug interactions: Delayed gastric emptying can affect absorption of co-administered narrow-therapeutic-index oral drugs ^[5].

Where it fits

Semaglutide is the most-studied compound on this desk and the one with the broadest regulatory approval. Its cardiovascular and kidney-outcome trial data extend well beyond weight loss into meaningful disease endpoints. Within this hub's metabolic theme, it is the reference point — the compound against which tirzepatide demonstrated superiority ^[1] and against which retatrutide's investigational profile is measured. Read alongside tirzepatide (dual agonist) and retatrutide (triple agonist) to see how each additional receptor target shifts the efficacy and safety picture. See the comparison page for a side-by-side.